Evaluation of PIV Score as a Predictor Biomarker for Pathologically Proven Intermediate-High Risk Gastric Gastrointestinal Stromal Tumors
Oktay Unsal1, Ahmet Ozet11Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Türkiye
Objectives: Pan-immune-inflammation value (PIV) score has been started to be used as a prognostic tool in cancer patients trendly in recent years. In this study, we aimed to evaluate the PIV score in patients with pathologically- proven intermediate-high risk gastric GIST to guide adjuvant therapy and to get better prognosis. Methods: Patients followed up by Medical Oncology clinic with a diagnosis of gastric GIST were evaluated retrospectively. Results: A total of 41 patients with a diagnosis of gastric GIST were examined. When the tumors were analyzed according to the AFIP prognostic model, 23 patients were identified as intermediate-high-risk tumors. According to the modified NIH model, intermediate-high risk tumors were noted in 26 patients. According to AFIP prognostic model, PIV scores were not different between risk groups (p=0.27). When the patients were classified according to modified NIH model, the platelet counts in patients with intermediate-high risk tumor were significanly higher than the other patients group (p=0.01). In addition, PIV scores were significantly higher in patients with intermediate-high risk tumor than other patients (p=0.03). Conclusion: This study displayed that PIV score can be useful as a risk predictor in patients with gastric GIST. Future prospective analysis are needed to support our results. Keywords: Gastric GIST, PIV score, modified NIH
Cite This Article
Unsal O, Ozet A. Evaluation of PIV Score as a Predictor Biomarker for Pathologically Proven Intermediate-High Risk Gastric Gastrointestinal Stromal Tumors. EJMI. 2024; 8(1): 67-72
Corresponding Author: Oktay Unsal